US Stock MarketDetailed Quotes

AVBP ArriVent BioPharma

Watchlist
  • 26.720
  • +0.840+3.25%
Close Dec 13 16:00 ET
  • 26.720
  • 0.0000.00%
Post 16:20 ET
900.39MMarket Cap-11.11P/E (TTM)

ArriVent BioPharma Key Stats

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
44.96%24.23M
13.78%25.7M
69.85%20.67M
102.11%74.59M
121.39%23.12M
42.05%16.72M
22.58M
12.17M
36.91M
10.44M
Selling and administrative expenses
70.11%4.14M
76.06%3.92M
91.06%3.7M
49.95%9.71M
73.15%3.11M
45.09%2.44M
--2.23M
--1.94M
--6.47M
--1.8M
-General and administrative expense
70.11%4.14M
76.06%3.92M
91.06%3.7M
49.95%9.71M
73.15%3.11M
45.09%2.44M
--2.23M
--1.94M
--6.47M
--1.8M
Research and development costs
40.67%20.09M
6.98%21.78M
65.84%16.98M
113.20%64.88M
131.41%20.01M
41.54%14.28M
--20.36M
--10.24M
--30.43M
--8.65M
Operating profit
-44.96%-24.23M
-13.78%-25.7M
-69.85%-20.67M
-102.11%-74.59M
-121.39%-23.12M
-42.05%-16.72M
-22.58M
-12.17M
-36.91M
-10.44M
Net non-operating interest income expense
58.44%3.67M
275.91%3.82M
3.26M
5.26M
1.93M
2.32M
1.02M
0
0
0
Non-operating interest income
58.44%3.67M
275.91%3.82M
--3.26M
--5.26M
--1.93M
--2.32M
--1.02M
--0
--0
--0
Other net income (expense)
Income before tax
-42.80%-20.56M
-1.42%-21.87M
-43.09%-17.42M
-87.86%-69.33M
-102.96%-21.19M
-22.37%-14.4M
-21.57M
-12.17M
-36.91M
-10.44M
Income tax
Net income
-42.80%-20.56M
-1.42%-21.87M
-43.09%-17.42M
-87.86%-69.33M
-102.96%-21.19M
-22.37%-14.4M
-21.57M
-12.17M
-36.91M
-10.44M
Net income continuous Operations
-42.80%-20.56M
-1.42%-21.87M
-43.09%-17.42M
-87.86%-69.33M
-102.96%-21.19M
-22.37%-14.4M
---21.57M
---12.17M
---36.91M
---10.44M
Minority interest income
Net income attributable to the parent company
-42.80%-20.56M
-1.42%-21.87M
-43.09%-17.42M
-87.86%-69.33M
-102.96%-21.19M
-22.37%-14.4M
-21.57M
-12.17M
-36.91M
-10.44M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-42.80%-20.56M
-1.42%-21.87M
-43.09%-17.42M
-87.86%-69.33M
-102.96%-21.19M
-22.37%-14.4M
-21.57M
-12.17M
-36.91M
-10.44M
Basic earnings per share
-35.36%-0.61
3.69%-0.65
-83.78%-0.7
-87.86%-2.1696
-102.96%-0.6632
-22.37%-0.4506
-0.6749
-0.3809
-1.1549
-0.3268
Diluted earnings per share
-35.36%-0.61
3.69%-0.65
-83.78%-0.7
-87.86%-2.1696
-102.96%-0.6632
-22.37%-0.4506
-0.6749
-0.3809
-1.1549
-0.3268
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion with Explanatory Notes
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 44.96%24.23M13.78%25.7M69.85%20.67M102.11%74.59M121.39%23.12M42.05%16.72M22.58M12.17M36.91M10.44M
Selling and administrative expenses 70.11%4.14M76.06%3.92M91.06%3.7M49.95%9.71M73.15%3.11M45.09%2.44M--2.23M--1.94M--6.47M--1.8M
-General and administrative expense 70.11%4.14M76.06%3.92M91.06%3.7M49.95%9.71M73.15%3.11M45.09%2.44M--2.23M--1.94M--6.47M--1.8M
Research and development costs 40.67%20.09M6.98%21.78M65.84%16.98M113.20%64.88M131.41%20.01M41.54%14.28M--20.36M--10.24M--30.43M--8.65M
Operating profit -44.96%-24.23M-13.78%-25.7M-69.85%-20.67M-102.11%-74.59M-121.39%-23.12M-42.05%-16.72M-22.58M-12.17M-36.91M-10.44M
Net non-operating interest income expense 58.44%3.67M275.91%3.82M3.26M5.26M1.93M2.32M1.02M000
Non-operating interest income 58.44%3.67M275.91%3.82M--3.26M--5.26M--1.93M--2.32M--1.02M--0--0--0
Other net income (expense)
Income before tax -42.80%-20.56M-1.42%-21.87M-43.09%-17.42M-87.86%-69.33M-102.96%-21.19M-22.37%-14.4M-21.57M-12.17M-36.91M-10.44M
Income tax
Net income -42.80%-20.56M-1.42%-21.87M-43.09%-17.42M-87.86%-69.33M-102.96%-21.19M-22.37%-14.4M-21.57M-12.17M-36.91M-10.44M
Net income continuous Operations -42.80%-20.56M-1.42%-21.87M-43.09%-17.42M-87.86%-69.33M-102.96%-21.19M-22.37%-14.4M---21.57M---12.17M---36.91M---10.44M
Minority interest income
Net income attributable to the parent company -42.80%-20.56M-1.42%-21.87M-43.09%-17.42M-87.86%-69.33M-102.96%-21.19M-22.37%-14.4M-21.57M-12.17M-36.91M-10.44M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -42.80%-20.56M-1.42%-21.87M-43.09%-17.42M-87.86%-69.33M-102.96%-21.19M-22.37%-14.4M-21.57M-12.17M-36.91M-10.44M
Basic earnings per share -35.36%-0.613.69%-0.65-83.78%-0.7-87.86%-2.1696-102.96%-0.6632-22.37%-0.4506-0.6749-0.3809-1.1549-0.3268
Diluted earnings per share -35.36%-0.613.69%-0.65-83.78%-0.7-87.86%-2.1696-102.96%-0.6632-22.37%-0.4506-0.6749-0.3809-1.1549-0.3268
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion with Explanatory Notes--
Heat List
US
Overall
Symbol
Price
% Chg

No Data